TRI - 医索

找到约 405 条结果

长寿新秘诀——拜谱多胺代谢是间歇性禁食抗衰老的关键因子

热量限制（caloric restriction, CR）和间歇性禁食（intermittent fasting, IF）在模式动物中被证实具有抗衰老和促进机体健康的作用。人体临床实验也表明间歇性或长期的禁食以及持续的热量限制干预对多个健康相关参数产生有利影响。自噬.....

学术资讯 - 临床医学

【期刊导读】预测HBeAg阴性慢性HBV感染者HBsAg清除的指标——TRIM19/38

编者按慢乙肝患者接受聚乙二醇干扰素α（PEG IFNα）治疗的临床疗效存在显著个体差异，更好地了解与PEG IFNα疗效相关的病毒学及宿主因素可能有助于提高疗效，实现更好的个体化治疗。近期已有多项研究报道三基序蛋白（TRIM）家.....

学术资讯 - 文献解读

Randomized phase lllll trial of gemcitabine plusnab-paclitaxel versus. concurrentchemoradiotherapy with S-1 as neoadjuvanttreatment for borderline resectable pancreaticcancerGABARNANCE study

医客学院 - 会议报告集

Ramucirumab plus paclitaxel as switch maintenanceversus continuation of oxaliplatin-based chemotherapyin patients with advanced HER2-negative gastric orgastroesophagealjunction cancerthe ARMAN

医客学院 - 会议报告集

New Tricks With Old Tools Acrossthe Spectrum of Pancreatic cancer

医客学院 - 会议报告集

Efficacy and Safety of Cadonilimab in Combination withPulocimab and Paclitaxel as Second-ine Therapy in Patientswith Advanced Gastric or Gastroesophageal Junction (GGEJ)Adenocarcinoma who Fail

医客学院 - 会议报告集

Early Results of the PASS-01 TrialPancreatic Adenocarcinoma Signature Stratification for Treatment

医客学院 - 会议报告集

SACI-0 HR A randomized phase ll trial ofsacituzumab govitecan with or without pembrolizumabin patients with metastatic hormone receptor-positive!HER2-negative breast cancer

医客学院 - 会议报告集

Primary results from PATRICIA Cohort c (SOLTI-1303)a randomized phase ll study evaluating palbociclib withtrastuzumab and endocrine therapy in pretreated HER2.positive and PAM50 luminal advanced b

医客学院 - 会议报告集

Enfortumab Vedotin in the HR HER2-and Triple-Negative Breast CancerCohorts of EV-202

医客学院 - 会议报告集

首页
上一页
1
2
3
4
5
...
40
41
下一页
尾页

今日实时热搜